International Registry Study: Data Collection to Improve Medical Care for Rare Brain Tumors

Medulloblastomas, ependymomas, pineoblastomas, and other so-called primitive neuroectodermal tumors of the central nervous system (CNS-PNETs) are rare, malignant brain tumors that can occur in both children and adults. They arise from various abnormal cells in the brain or spinal cord—that is, in the central nervous system (CNS). Although they are rare, CNS tumors are among the most common solid cancers in children and adolescents. Medulloblastomas and ependymomas are particularly common. The causes are not yet fully understood, but genetic changes play an important role.

Standard treatment usually involves a combination of surgery, followed by radiation therapy and chemotherapy. Since many patients cannot participate in clinical trials due to their age, tumor stage, or other factors, they are treated outside of such trials according to established treatment guidelines. However, the lack of inclusion in structured study protocols makes it difficult to systematically record and scientifically evaluate treatments and disease progression. These data are important for developing comprehensive, evidence-based guidelines and further improving treatment.

The goal of the I-HIT-MED study is to use clinical data to better understand how frequently these rare tumors occur (epidemiology), how they are treated, and what treatment outcomes are achieved. In addition, the registry is intended to help develop and improve standards for diagnosis and treatment. This will help establish uniform quality standards for care, both in countries where such systems already exist and in those where they are still lacking. Another focus is on the collection and analysis of biological samples such as tumor tissue, cerebrospinal fluid (CSF), and blood. This does not require any additional time on the part of patients, as data collection is primarily passive—that is, it takes place in the background through the recording of standard medical data and biological samples provided by the treating practices or hospitals.

Children, adolescents, and adults who were diagnosed with one of the following brain tumors after January 1, 2012, are eligible to participate: medulloblastoma, ependymoma, pineoblastoma, papillary tumor of the pineal region, tumor of the pineal parenchyma with intermediate differentiation, or other so-called primitive neuroectodermal tumors of the central nervous system (CNS-PNET), such as CNS neuroblastoma, ganglioneuroblastoma, medulloepithelioma, or ependymoblastoma. For certain tumors, the diagnosis must have been made before the patient’s 18th birthday. A relapse may, under certain conditions, be considered a new diagnosis, so participation may still be possible under specific circumstances. Participation is possible regardless of the tumor’s location in the CNS and the stage of the disease. The prerequisite is that the patient has not been enrolled in another prospective clinical trial for the same diagnosis.